{"name": "ARIAD Pharmaceuticals",
 "permalink": "ariad-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/ariad-pharmaceuticals",
 "homepage_url": "http://www.ariad.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": null,
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": null,
 "alias_list": "",
 "email_address": "investor@ariad.com",
 "phone_number": "(617) 494-0400",
 "description": "biotechnology company ",
 "created_at": "Mon Aug 30 21:32:04 UTC 2010",
 "updated_at": "Fri Aug 19 01:37:19 UTC 2011",
 "overview": "\u003Cp\u003EARIAD is a Cambridge, Massachusetts-based biotechnology company focused on cancer. We are a cohesive team of talented people from diverse backgrounds with a shared vision: We seek to transform the lives of patients with breakthrough cancer medicines. This is our purpose. This is our passion. This is our promise.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       104],
      "assets/images/resized/0010/8537/108537v1-max-150x150.png"],
     [[151,
       105],
      "assets/images/resized/0010/8537/108537v1-max-250x250.png"],
     [[151,
       105],
      "assets/images/resized/0010/8537/108537v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": true,
    "title": "Co-Founder",
    "person":
     {"first_name": "Larry",
      "last_name": "Bock",
      "permalink": "larry-bock",
      "image":
       {"available_sizes":
         [[[110,
            150],
           "assets/images/resized/0009/9950/99950v1-max-150x150.jpg"],
          [[183,
            250],
           "assets/images/resized/0009/9950/99950v1-max-250x250.jpg"],
          [[330,
            450],
           "assets/images/resized/0009/9950/99950v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "HQ",
    "address1": "26 Landsdowne Street ",
    "address2": "",
    "zip_code": "02139-4234",
    "city": "Cambridge",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "announced a stock offering to help fund tests on a treatment for chronic myeloid leukemia, while also reporting that a Phase 2 study of its treatment for endometrial cancer showed significant improvements in progression-free survival",
    "stoned_year": 2010,
    "stoned_month": 10,
    "stoned_day": 26,
    "source_url": "http://www.masshightech.com/stories/2010/10/25/daily14-ARIAD-reports-positive-test-results-plans-stock-offering.html",
    "source_text": null,
    "source_description": "ARIAD reports positive test results, plans stock offering",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "ARIAD Pharmaceuticals",
      "permalink": "ariad-pharmaceuticals"}},
   {"description": "the pivotal Phase 3 safety and efficacy trial of ridaforolimus, its drug candidate for metastatic soft-tissue or bone sarcomas, met its primary endpoint",
    "stoned_year": 2011,
    "stoned_month": 1,
    "stoned_day": 18,
    "source_url": "http://www.masshightech.com/stories/2011/01/17/daily19-Ariad-sees-positive-results-on-pivotal-sarcoma-trial.html",
    "source_text": null,
    "source_description": "Ariad sees positive results on pivotal sarcoma trial",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "ARIAD Pharmaceuticals",
      "permalink": "ariad-pharmaceuticals"}},
   {"description": "Ariad gets $25M milestone payment from Merck",
    "stoned_year": 2011,
    "stoned_month": 8,
    "stoned_day": 18,
    "source_url": "http://www.masshightech.com/stories/2011/08/15/daily42-Ariad-gets-25M-milestone-payment-from-Merck.html",
    "source_text": "",
    "source_description": "Ariad gets $25M milestone payment from Merck",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "ARIAD Pharmaceuticals",
      "permalink": "ariad-pharmaceuticals"}}],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": null,
   "pub_month": null,
   "pub_day": null,
   "stock_symbol": "NASDAQ:ARIA"},
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        128],
       "assets/images/resized/0010/8539/108539v1-max-150x150.jpg"],
      [[250,
        213],
       "assets/images/resized/0010/8539/108539v1-max-250x250.jpg"],
      [[450,
        384],
       "assets/images/resized/0010/8539/108539v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}